Biogen's $7.22 per share buyout offer signals confidence in Sage's commercial potential and drug pipeline. Read why SAGE ...

Sage Therapeutics faces challenges with a 90% value drop but shows promise with Zurzuvae for postpartum depression. Click ...

Last year, the first phase 3 trial of Sage Therapeutics and Biogen's antidepressant hopeful zuranolone hit its efficacy targets, but raised doubts about the durability of the response. Now ...

Sage Therapeutics has left its view of Biogen's recent takeover bid in little doubt – it has just filed a lawsuit seeking to block the deal. Specific details of the lawsuit are not yet available ...

12:42 PM ESTHealth Care Biogen offers to buy out Sage Therapeutics Biogen offers to buy out Sage Therapeutics ...

Sage Therapeutics, Inc. (SAGE ... depression drug Zurzuvae (zuranolone), which is marketed in partnership with Biogen. Zurzuvae is the first and only oral treatment indicated for adults with ...

In a report released today, Vikram Purohit from Morgan Stanley maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report), with a ...

NASDAQ:SAGE opened at $8.28 on Friday. The company has a 50 day simple moving average of $7.48 and a two-hundred day simple moving average of $6.73. The company has a market cap of $509.06 million ...

$50,000 of SAGE THERAPEUTICS lobbying was just disclosed, from Q1 of 2025, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "Education and awareness of mental health ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the ...